| scholarly article | Q13442814 |
| P50 | author | Pieter A van Doorn | Q66672518 |
| Bart C Jacobs | Q66672643 | ||
| P2093 | author name string | Hugh J Willison | |
| P2860 | cites work | Reversible conduction failure is distinct from neurophysiological patterns of recovery in mild demyelinating Guillain-Barré syndrome | Q86086075 |
| Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes | Q86637921 | ||
| Paraparetic Guillain-Barré syndrome | Q87833741 | ||
| Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis | Q22241939 | ||
| Immunotherapy for Guillain-Barre syndrome: a systematic review | Q22242913 | ||
| Guillain–Barré Syndrome | Q22248108 | ||
| Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis | Q22251013 | ||
| Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data | Q22251433 | ||
| Glycolipid antigens and autoantibodies in autoimmune neuropathies | Q22252419 | ||
| Assessment of current diagnostic criteria for Guillain-Barré syndrome | Q22252936 | ||
| The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study | Q22306168 | ||
| Zika virus: following the path of dengue and chikungunya? | Q22330711 | ||
| Pharmacological treatment for pain in Guillain-Barré syndrome | Q24186580 | ||
| Intravenous immunoglobulin for Guillain-Barré syndrome | Q24193522 | ||
| Plasma exchange for Guillain-Barré syndrome | Q24202179 | ||
| Guillain-Barré syndrome | Q24276200 | ||
| Guillain-Barré syndrome after exposure to influenza virus | Q28291850 | ||
| Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome | Q28297319 | ||
| Health-related quality of life in Guillain-Barré syndrome patients: a systematic review | Q28306474 | ||
| Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis | Q30428338 | ||
| Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange | Q33590031 | ||
| Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. | Q34130499 | ||
| Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977 | Q34215590 | ||
| Pure sensory Guillain-Barré syndrome: A case report and review of the literature | Q34292453 | ||
| Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. | Q34435977 | ||
| Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh | Q34616731 | ||
| Early recognition of poor prognosis in Guillain-Barre syndrome | Q34686090 | ||
| Guillain-Barré syndrome in northern China Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies | Q34720415 | ||
| Peripheral neuropathies and anti-glycolipid antibodies | Q34995419 | ||
| Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome | Q35072720 | ||
| Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies | Q35713309 | ||
| Mortality in mechanically ventilated patients of Guillain Barré Syndrome | Q35732156 | ||
| Familial Guillain-Barré syndrome: First Indian report | Q35820672 | ||
| The immunobiology of Guillain-Barré syndromes | Q36164122 | ||
| Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients | Q36317212 | ||
| Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction | Q37535345 | ||
| Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy | Q37625983 | ||
| Animal models of autoimmune neuropathy | Q37655234 | ||
| A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies | Q38002974 | ||
| Outcome and its predictors in Guillain-Barre syndrome | Q38008314 | ||
| Fatigue in immune-mediated neuropathies. | Q38062689 | ||
| The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy | Q38070878 | ||
| Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). | Q38102838 | ||
| Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies | Q38103652 | ||
| 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands | Q38120132 | ||
| The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. | Q38185209 | ||
| Guillain-Barré syndrome in Arab countries: a systematic review | Q38221982 | ||
| Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes | Q38252747 | ||
| Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study | Q38300498 | ||
| Mechanisms of distal axonal degeneration in peripheral neuropathies. | Q38330759 | ||
| Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders | Q38333532 | ||
| A 15-Year Nationwide Epidemiological Analysis of Guillain-Barré Syndrome in Taiwan | Q38414092 | ||
| Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. | Q38985636 | ||
| Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions | Q39157513 | ||
| Mortality in Guillain-Barre syndrome | Q39436661 | ||
| A clinical prognostic scoring system for Guillain-Barré syndrome | Q40208214 | ||
| Innate Immunity to Campylobacter jejuni in Guillain-Barré Syndrome | Q41199354 | ||
| Guillain-Barré syndrome associated with preceding hepatitis E virus infection | Q42243837 | ||
| Binational outbreak of Guillain-Barré syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. | Q42252014 | ||
| Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands | Q43071161 | ||
| Subacute inflammatory demyelinating polyneuropathy | Q44685033 | ||
| Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial | Q44738594 | ||
| Residual fatigue in Guillain-Barre syndrome is related to axonal loss | Q44802824 | ||
| Pain in Guillain-Barre syndrome: a long-term follow-up study | Q45053372 | ||
| Ganglioside complexes as new target antigens in Guillain-Barré syndrome | Q45076567 | ||
| Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles | Q46102964 | ||
| Hepatitis E and Guillain-Barre syndrome | Q46195844 | ||
| Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study | Q46393671 | ||
| Supportive care for patients with Guillain-Barré syndrome | Q46640922 | ||
| Long-term outcome of Guillain-Barré syndrome in children | Q47871099 | ||
| Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice | Q48180410 | ||
| Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria | Q48909912 | ||
| Recognizing Guillain-Barre syndrome in preschool children. | Q51052942 | ||
| Ranvier revisited: novel nodal antigens stimulate interest in GBS pathogenesis. | Q51845902 | ||
| Recurrences, vaccinations and long-term symptoms in GBS and CIDP. | Q53087005 | ||
| An open label clinical trial of complement inhibition in multifocal motor neuropathy. | Q53239243 | ||
| Conduction block in acute motor axonal neuropathy | Q53299856 | ||
| Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. | Q53506236 | ||
| Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody. | Q54513832 | ||
| Campylobacter jejuni infection and Guillain-Barré syndrome. | Q55063212 | ||
| Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes | Q56771825 | ||
| Clinical predictors of mechanical ventilation in Fisher/Guillain-Barre overlap syndrome | Q56772003 | ||
| Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial | Q56900236 | ||
| Electrodiagnosis of GBS subtypes by a single study: not yet the squaring of the circle | Q57769414 | ||
| Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies | Q70514545 | ||
| Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome | Q71444464 | ||
| Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? | Q72843312 | ||
| Haemophilus influenzae infection and Guillain-Barré syndrome | Q72998265 | ||
| The risk of Guillain-Barré syndrome following infection with Campylobacter jejuni | Q74658529 | ||
| Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group | Q77568588 | ||
| Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome | Q78076494 | ||
| Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome | Q80453136 | ||
| Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy | Q80533753 | ||
| Immune responses to myelin proteins in Guillain-Barré syndrome | Q80838078 | ||
| The occurrence of Guillain-Barre syndrome within families | Q80980747 | ||
| Biomarkers in experimental models of antibody-mediated neuropathies | Q84420223 | ||
| Non-demyelinating, reversible conduction failure in Fisher syndrome and related disorders | Q84530892 | ||
| Are ERM (ezrin/radixin/moesin) proteins targets for autoantibodies in demyelinating neuropathies? | Q85686704 | ||
| P433 | issue | 10045 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Guillain–Barré syndrome | Q205214 |
| P304 | page(s) | 717-27 | |
| P577 | publication date | 2016-08-13 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Guillain-Barré syndrome | |
| P478 | volume | 388 |
| Q95654069 | "Claw hand with a unilateral onset" as a regional variant of Guillain-Barre' syndrome: A case report |
| Q92400041 | 7T MR neurography-ultrasound fusion for peripheral nerve imaging |
| Q89311148 | A Case Report of Overlapping Miller Fisher Syndrome, Guillain-Barré Syndrome, and the Bickerstaff Brainstem Encephalitis |
| Q100296965 | A Case of Guillain-Barré Syndrome Associated With COVID-19 |
| Q102323324 | A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides |
| Q24261408 | A Mouse Model of Zika Virus Pathogenesis |
| Q52579206 | A Patient With Encephalomyeloradiculoneuropathy Exhibiting a Relapsing-Remitting Clinical Course: Correlation of Serum and Cerebrospinal Fluid Anti-Neutral Glycosphingolipids Antibodies With Clinical Relapse. |
| Q38401935 | A Patient as Art: Andrew Wyeth's Portrayal of Christina Olson's Neurologic Disorder in Christina's World |
| Q64270489 | A Rare Case of HIV-Induced Inflammatory Demyelinating Polyneuropathy |
| Q89866046 | A cohort study: The Association Between Autoimmune Disorders and Leptospirosis |
| Q28595402 | A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia |
| Q90355720 | A follow-up study on Guillain-Barre syndrome and validation of Brighton criteria |
| Q96122600 | A nomogram to predict mechanical ventilation in Guillain-Barré syndrome patients |
| Q99560709 | A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection |
| Q92766432 | A rare mimic of acute stroke: rapidly progressing Miller-Fisher Syndrome to acute motor and sensory axonal neuropathy variant of Guillain-Barre Syndrome |
| Q91513747 | A robust and novel electrical impedance metric of pulmonary function in ALS patients |
| Q92926132 | A simulation study of the statistical power and signaling characteristics of an early season sequential test for influenza vaccine safety |
| Q90589356 | Acute Complications and Sequelae from Foodborne Infections: Informing Priorities for Cost of Foodborne Illness Estimates |
| Q43047287 | Acute Zika Virus Infection as a Risk Factor for Guillain-Barré Syndrome in Puerto Rico |
| Q98661406 | Acute and chronic neuropathies |
| Q88628652 | Acute axonal neuropathy subtype of Guillain Barré syndrome in a French pediatric series: Adequate follow-up may require repetitive electrophysiological studies |
| Q92139703 | Acute flaccid myelitis and enterovirus D68: lessons from the past and present |
| Q104567507 | Acute flaccid myelitis: cause, diagnosis, and management |
| Q93056427 | Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound |
| Q90736251 | Advances in management of Guillain-Barré syndrome |
| Q89843698 | Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS) |
| Q101153051 | Altered mental status in "Guillain-Barré syndrome" -a noteworthy clinical clue |
| Q31129434 | An Imaging-Based Approach to Spinal Cord Infection. |
| Q91072457 | An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model |
| Q44843450 | Analysing increasing trends of Guillain-Barré Syndrome (GBS) and dengue cases in Hong Kong using meteorological data |
| Q91241587 | Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study |
| Q89172471 | Anti-ganglioside Antibodies in Peripheral Nerve Pathology |
| Q50950878 | Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis. |
| Q38900490 | Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies |
| Q100504762 | Antigenic Variability a Potential Factor in Assessing Relationship Between Guillain Barré Syndrome and Influenza Vaccine - Up to Date Literature Review |
| Q89987648 | Association between Helicobacter pylori infection and Guillain-Barré Syndrome: A meta-analysis |
| Q50044487 | Association of Neutrophil/Lymphocyte Ratio With Intravenous Immunoglobulin Treatment in Children With Guillain-Barré Syndrome |
| Q95647008 | Association of matrix metalloproteinase-9 polymorphism with severity of Guillain-Barré syndrome |
| Q103812449 | Associations of body mass index and waist circumference with risk of Guillain-Barré syndrome in women and men: A prospective analysis of three cohort studies |
| Q98190608 | Asymmetric Lower Extremity Involvement and Facial Palsy: An Atypical Case of Guillain-Barre Syndrome |
| Q90206347 | Atypical Lyme Neuroborreliosis, Guillain-Barré Syndrome or Conversion Disorder: Differential Diagnosis of Unusual Neurological Presentations |
| Q102129638 | Atypical Variant of Guillain Barre Syndrome in a Patient with COVID-19 |
| Q55026039 | Autoimmune Neurological Conditions Associated With Zika Virus Infection. |
| Q91035982 | Autoimmune Neuromuscular Diseases Induced by Immunomodulating Drugs |
| Q96824683 | Axonal degeneration in Guillain-Barré syndrome: a reappraisal |
| Q91130003 | Ayurveda management of Guillain-Barre syndrome: A case report |
| Q55278773 | Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis. |
| Q93034884 | Bioactive Glass in a Rare Case of Osteomyelitis of the Heel in a Guillain-Barré Syndrome: A Case Report |
| Q60920726 | Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis |
| Q101343419 | Burden of Disease of Guillain-Barré Syndrome in Brazil before and during the Zika virus epidemic 2014 - 2016 |
| Q96684751 | COVID-19-Associated Bifacial Weakness with Paresthesia Subtype of Guillain-Barré Syndrome |
| Q103731580 | COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications |
| Q97551285 | COVID-19-Associated Guillain-Barre Syndrome: The Early Pandemic Experience |
| Q89767354 | Case 1: Unilateral Leg Pain and Difficulty Walking |
| Q89896637 | Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barré Syndrome |
| Q93107554 | Cerebrospinal Fluid (CSF) Analysis and Interpretation in Neurocritical Care for Acute Neurological Conditions |
| Q91309680 | Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology |
| Q37680036 | Changes in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year period. |
| Q50137527 | Characteristics, incidence and outcome of patients admitted to intensive care unit with Guillain-Barre syndrome in Australia and New Zealand |
| Q90734781 | Charcot Arthropathy of the Shoulder Joint in a Patient with Guillain-Barré Syndrome: A Case Report |
| Q101464062 | Chemoenzymatic Synthesis of Campylobacter jejuni Lipo-oligosaccharide Core Domains to Examine Guillain-Barré Syndrome Serum Antibody Specificities |
| Q91762785 | Chikungunya, a Risk Factor for Guillain-Barré Syndrome |
| Q43528346 | Chronic arsenic intoxication diagnostic score (CAsIDS). |
| Q90194403 | Clinical Characteristics and Electrodiagnostic Features of Guillain-Barré Syndrome Among the Pediatric Population |
| Q64086874 | Clinical Characteristics of Intravenous Injection of Monosialotetrahexosyl Ganglioside Sodium-Related Guillain-Barre Syndrome |
| Q55084445 | Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016. |
| Q55519293 | Clinical Heterogeneity of Anti-GM2-Ganglioside-Antibody Syndrome. |
| Q91406871 | Clinical Performance Measures for Neurocritical Care: A Statement for Healthcare Professionals from the Neurocritical Care Society |
| Q40116763 | Clinical and electrophysiological features of post-traumatic Guillain-Barré syndrome. |
| Q89687462 | Clinical characteristics and outcomes of patients with overlapping Miller Fisher syndrome and myasthenia gravis |
| Q88299859 | Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation |
| Q52603587 | Clinical, Serological, and Molecular Observations from a Case Series Study during the Asian Lineage Zika Virus Outbreak in Grenada during 2016. |
| Q94352127 | Commentary |
| Q104507696 | Complications and Pathophysiology of COVID-19 in the Nervous System |
| Q58605860 | Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review |
| Q100697047 | Concurrent acute myositis and Guillain-Barre syndrome in Cytomegalovirus infection - a rare case report |
| Q90728674 | Correlations between microRNA-146a and immunoglobulin and inflammatory factors in Guillain-Barré syndrome |
| Q92424468 | Correspondence: Guillain-Barré syndrome and hemorrhagic fever with renal syndrome |
| Q38989370 | Corticosteroids for Guillain-Barré syndrome |
| Q92595685 | Current treatment practice of Guillain-Barré syndrome |
| Q89980146 | Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity |
| Q99726129 | Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines |
| Q48633757 | Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome |
| Q90197754 | Diagnosis and management of Guillain-Barré syndrome in ten steps |
| Q91862045 | Diagnosis and management of sensory polyneuropathy |
| Q91349379 | Diagnosis and treatment of Guillain-Barré syndrome during the Zika virus epidemic in Brazil: A national survey study |
| Q57300562 | Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies |
| Q95359883 | Diaphragmatic dysfunction |
| Q52617290 | Differences between Acute-onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) and Acute Inflammatory Demyelinating Polyneuropathy (AIDP) in adult patients. |
| Q41922238 | Diseases of the peripheral nerves. |
| Q90381013 | Distal limb weakness phenotype of Guillain-Barré syndrome |
| Q93137088 | Dysautonomia and hyponatraemia as harbingers of Guillain-Barre syndrome |
| Q90754302 | Dysglycemia and Neurologic Outcome in Mechanically Ventilated Patients With Guillain-Barré Syndrome |
| Q41986460 | Early predictors of Guillain-Barré syndrome in the life course of women |
| Q92146462 | Effect of fasudil on experimental autoimmune neuritis and its mechanisms of action |
| Q53694421 | Effects of antibiotic resistance (AR) and microbiota shifts on Campylobacter jejuni-mediated diseases. |
| Q92106165 | Electrophysiological Subtypes and Prognostic Factors of Guillain-Barre Syndrome in Northern China |
| Q98244275 | Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience |
| Q56380747 | Emerging sexually transmitted viral infections: 2. Review of Zika virus disease |
| Q55218978 | Enhanced Biofilm Formation by Ferrous and Ferric Iron Through Oxidative Stress in Campylobacter jejuni. |
| Q33854582 | Eosinophilic Granulomatosis with Polyangiitis Presented as Acute Polyneuropathy and Cerebral Vasculitis |
| Q97433754 | Epidemiological and Whole Genomic Sequencing Analysis of a Campylobacter jejuni Outbreak in Zhejiang Province, China, May 2019 |
| Q48313524 | Experimental Guillain-Barre syndrome induced by immunization with gangliosides: Keyhole limpet hemocyanin is required for disease triggering |
| Q92151346 | Explaining Pathogenicity of Congenital Zika and Guillain-Barré Syndromes: Does Dysregulation of RNA Editing Play a Role? |
| Q98197788 | Exploring the experiences of having Guillain-Barré Syndrome: A qualitative interview study |
| Q97647385 | Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome |
| Q90774780 | Fatal, paraparetic acute motor axonal neuropathy, early complicating chemotherapy with nab-paclitaxel |
| Q91713597 | Fecal Microbiota Transplantation in Neurological Disorders |
| Q98725209 | Frequency of five unusual presentations in patients with COVID-19: Results of the UMC-19-S1 |
| Q97882869 | Fulminant Guillain-Barré Syndrome and Spontaneous Intraventricular Hemorrhage: A Case Report and Literature Review |
| Q91044091 | Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus |
| Q49483052 | Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study |
| Q54215171 | Gangliosides and Autoimmune Peripheral Nerve Diseases. |
| Q64101031 | Genetic landscape and macro-evolution of co-circulating Coxsackieviruses A and Vaccine-derived Polioviruses in the Democratic Republic of Congo, 2008-2013 |
| Q99574223 | Genetic polymorphisms in Guillain-Barré Syndrome: A field synopsis and systematic meta-analysis |
| Q92280641 | Genomic Analysis of Chilean Strains of Campylobacter jejuni from Human Faeces |
| Q90806943 | Glycoreplica peptides to investigate molecular mechanisms of immune-mediated physiological versus pathological conditions |
| Q92628861 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue |
| Q104475855 | Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series |
| Q52681339 | Guillain, Barraquer and I. |
| Q98719950 | Guillain-Barre Syndrome Variant as a Rare Complication of Leptospirosis |
| Q54247318 | Guillain-Barre syndrome associated with hemorrhagic fever with renal syndrome in China: a case report. |
| Q98900503 | Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports |
| Q94598036 | Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature |
| Q92519500 | Guillain-Barre syndrome: a rare complication of leptospirosis and scrub typhus co-infection |
| Q50119727 | Guillain-BarrÉ syndrome subtype diagnosis: A prospective multicentric European study. |
| Q89121519 | Guillain-Barré Syndrome |
| Q41524053 | Guillain-Barré Syndrome After Revision Lumbar Surgery: A Case Report |
| Q27107337 | Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia |
| Q103725878 | Guillain-Barré Syndrome Heralding the Diagnosis of Hodgkin Lymphoma: A Case Report |
| Q47695468 | Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review |
| Q40047432 | Guillain-Barré Syndrome and Chikungunya: Description of All Cases Diagnosed during the 2014 Outbreak in the French West Indies |
| Q90680136 | Guillain-Barré Syndrome and Posterior Reversible Encephalopathy Syndrome following Spinal Surgery |
| Q40053492 | Guillain-Barré Syndrome in Pregnancy |
| Q38780487 | Guillain-Barré Syndrome, variants & forms fruste: Reclassification with new criteria |
| Q107214409 | Guillain-Barré syndrome |
| Q96350892 | Guillain-Barré syndrome after SARS-CoV-2 infection |
| Q98733210 | Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes |
| Q93009955 | Guillain-Barré syndrome after viral hepatitis A |
| Q101409613 | Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions |
| Q91905806 | Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009-2015 |
| Q91997275 | Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients |
| Q99593480 | Guillain-Barré syndrome associated with COVID-19 disease |
| Q101044233 | Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis |
| Q62485147 | Guillain-Barré syndrome associated with Zika virus infection in Brazil: a cost-of-illness study |
| Q89722001 | Guillain-Barré syndrome complicated by takotsubo cardiomyopathy: an under-recognised association |
| Q96429057 | Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication |
| Q93218066 | Guillain-Barré syndrome following COVID-19: new infection, old complication? |
| Q40631137 | Guillain-Barré syndrome following acute co-super-infection of hepatitis E virus and cytomegalovirus in a chronic hepatitis B virus carrier |
| Q60044378 | Guillain-Barré syndrome following bacterial meningitis: a case report and literature review |
| Q50146245 | Guillain-Barré syndrome following varicella-zoster virus infection |
| Q39402807 | Guillain-Barré syndrome in Bangladesh: validation of Brighton criteria |
| Q31149945 | Guillain-Barré syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008-2013). |
| Q92433920 | Guillain-Barré syndrome in a cancer patient treated with bevacizumab |
| Q91859701 | Guillain-Barré syndrome in a heart transplantation recipient |
| Q91791946 | Guillain-Barré syndrome in a man presenting with upper extremity monoplegia |
| Q100517425 | Guillain-Barré syndrome in a patient previously diagnosed with COVID-19 |
| Q90735109 | Guillain-Barré syndrome in a patient with multiple myeloma after bortezomib therapy: A case report |
| Q53291730 | Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy. |
| Q39415980 | Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity |
| Q43046804 | Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl |
| Q99416945 | Guillain-Barré syndrome presenting with COVID-19 infection |
| Q98719048 | Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases |
| Q47227139 | Guillain-Barré syndrome with exaggerated pleocytosis and anti-GM1 ganglioside antibodies |
| Q95940395 | Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection |
| Q47548537 | Guillain-Barré syndrome, transverse myelitis and infectious diseases. |
| Q92060050 | Guillain-Barré syndrome-the challenge of unrecognized triggers |
| Q51345262 | Guillain-Barré syndrome. |
| Q26973005 | Guillain-Barré syndrome: What have we learnt during one century? A personal historical perspective |
| Q92563044 | Guillain-Barré syndrome: looking back… and forward |
| Q89894105 | Guillain-Barré syndrome: surveillance and cost of treatment strategies |
| Q89894108 | Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' reply |
| Q53550821 | Guillain-Barré syndrome: surveillance and cost of treatment strategies. |
| Q100419766 | HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome |
| Q38716400 | Hepatitis E Virus Infects Neurons and Brains. |
| Q91908249 | Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature |
| Q93235844 | High-Risk Chief Complaints III: Neurologic Emergencies |
| Q42993195 | How Zika virus made the transition from being a virtually unknown virus to a high-profile public health threat |
| Q66679189 | Human Schwann cells are susceptible to infection with Zika and yellow fever viruses, but not dengue virus |
| Q89564246 | Human parechovirus type 6 and Guillain-Barré syndrome: a case report |
| Q60933975 | IVIg-induced plasmablasts in patients with Guillain-Barré syndrome |
| Q98191400 | Identifying the culprits in neurological autoimmune diseases |
| Q58581491 | IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target? |
| Q92949792 | Immune-Mediated Neuropathies |
| Q97680338 | Immune-Mediated Neuropathies |
| Q93027406 | Immune-mediated adverse reactions to vaccines |
| Q57476569 | Immune-mediated neuropathies |
| Q97873543 | Immunopathogenesis of alphaviruses |
| Q61053754 | Implementation and Evaluation of Guillain-Barré Syndrome Surveillance in Puerto Rico during the 2016 Zika Virus Epidemic |
| Q90499333 | Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study |
| Q64257770 | Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis |
| Q30145644 | Incidence and clinical characteristics of Guillain-Barré syndrome before the introduction of Zika virus in Puerto Rico |
| Q99637968 | Incidence and mortality rates of Guillain-Barré syndrome in Serbia |
| Q92867210 | Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis |
| Q98202389 | Incidence of Guillain-Barré Syndrome is not Associated with Influenza Vaccination in the Elderly |
| Q91707942 | Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation |
| Q104102214 | Increased Cerebrospinal Fluid Uric Acid Levels in Guillain-Barré Syndrome |
| Q40037956 | Increased rates of Guillain-Barré syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. |
| Q64970425 | Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. |
| Q41918109 | Insights into the molecular roles of Zika virus in human reproductive complications and congenital neuropathologies |
| Q38730827 | International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome |
| Q100509675 | Involvement of the nervous system in COVID-19: The bell should toll in the brain |
| Q40140618 | Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Toward a Universal Influenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development |
| Q92794248 | Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab |
| Q63248437 | Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches |
| Q58615385 | Lessons from a Life: The Manuel Tapia Lecture 2018 |
| Q98665214 | Lifting the mask on neurological manifestations of COVID-19 |
| Q47289931 | Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study |
| Q101043665 | Mechanical ventilation in Guillain-Barré syndrome |
| Q102216565 | Miller-Fisher Syndrome: A Case Report and Review of the Literature |
| Q101470028 | Mini Review: Lipids in peripheral nerve disorders |
| Q93157216 | Most of anti-glycolipid IgG-antibodies associated to neurological disorders occur without their IgM counterpart |
| Q55153878 | Motor Nerve Conduction Block Predicting Outcome of Guillain-Barre Syndrome. |
| Q111911746 | Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities |
| Q58455202 | Myelin-derived and putative molecular mimic peptides share structural properties in aqueous and membrane-like environments |
| Q49279103 | Myelinating Schwann Cell Polarity and Mechanically-Driven Myelin Sheath Elongation. |
| Q90539204 | N-glycosylation of the CmeABC multidrug efflux pump is needed for optimal function in Campylobacter jejuni |
| Q54217649 | Nervous System Injury and Neuroimaging of Zika Virus Infection. |
| Q91159164 | Neurobiology and therapeutic applications of neurotoxins targeting transmitter release |
| Q90047024 | Neurogenic heterotopic ossification in Guillain-Barre syndrome: a rare case report |
| Q47558320 | Neurological Implications of Zika Virus Infection in Adults |
| Q38156712 | Neurological Presentation of Zika Virus Infection Beyond the Perinatal Period. |
| Q39004668 | Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications |
| Q97075306 | Neurological associations of COVID-19 |
| Q92894896 | Neurological complications associated with emerging viruses in Brazil |
| Q96610556 | Neurological involvement of coronavirus disease 2019: a systematic review |
| Q97521882 | Neurological manifestations of COVID-19: a systematic review |
| Q27927995 | Neurological manifestations of Zika virus infection |
| Q102201921 | Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral' |
| Q39042513 | Neuropathic and Myopathic Pain |
| Q91981271 | Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma |
| Q50087251 | Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases |
| Q47126672 | Novel pathomechanisms in inflammatory neuropathies |
| Q88100160 | Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis |
| Q61797860 | Outbreak of Guillain-Barre syndrome in Peru |
| Q47203905 | Outcome of Guillain-Barré Syndrome in Tertiary Care Centers in Thailand. |
| Q93379188 | Outcomes of patients with Guillain Barre Syndrome - Experience from a tertiary care hospital of a developing Asian country and review of regional literature |
| Q39016213 | PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production |
| Q92157275 | Papillary thyroid carcinoma presenting with severe Guillain-Barré syndrome |
| Q92243481 | Paralytic ileus as the presenting symptom for Guillain-Barré syndrome: a case report |
| Q64075382 | Peripheral Demyelinating Diseases: From Biology to Translational Medicine |
| Q42106267 | Peroral endoscopic myotomy for treatment of Guillain-Barre syndrome-associated achalasia: A rare case |
| Q92936582 | Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome |
| Q90171784 | Physiology of gangliosides and the role of antiganglioside antibodies in human diseases |
| Q57689726 | Plasma exchange for Guillain-Barré syndrome |
| Q39071046 | Plasmapheresis and other extracorporeal filtration techniques in critical patients. |
| Q52686427 | Polyneuropathies. |
| Q96645082 | Polyneuropathy in Young Siberian Huskies Caused by Degenerative and Inflammatory Diseases |
| Q58765108 | Possible Association of Papillophlebitis with Guillain-Barré Syndrome: Case Report |
| Q99565499 | Post-infectious neurological disorders |
| Q97085744 | Posterior reversible encephalopathy in a GT1a positive oculopharyngeal variant of Guillain-Barré syndrome: A case-report and review of the literature |
| Q47558426 | Postmortem Findings in Patient with Guillain-Barré Syndrome and Zika Virus Infection |
| Q40043727 | Practical approach to the patient with acute neuromuscular weakness |
| Q101049872 | Pragmatic approach to neuraxial anesthesia in obstetric patients with disorders of the vertebral column, spinal cord and neuromuscular system |
| Q87864906 | Predictive factors for achieving independent walking in children with Guillain-Barre syndrome |
| Q47758232 | Primary Acute Neuromuscular Respiratory Failure |
| Q90156488 | Prognostic factors for the sequelae and severity of Guillain-Barré syndrome in children |
| Q38868347 | Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification |
| Q109918895 | Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
| Q100497882 | Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome |
| Q28804115 | Real-Time Assessment of Health-Care Requirements During the Zika Virus Epidemic in Martinique |
| Q57927215 | Regional variation of Guillain-Barré syndrome |
| Q38900486 | Respiratory failure because of neuromuscular disease |
| Q27468755 | Response: Commentary: Zika Virus: the Latest Newcomer |
| Q64106963 | Retail liver juices enhance the survivability of Campylobacter jejuni and Campylobacter coli at low temperatures |
| Q104475724 | Review of indications for immunoglobulin (IG) use: narrowing the gap between supply and demand |
| Q94523510 | Risk factors for mechanical ventilation in children with Guillain-Barré syndrome |
| Q91692209 | Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis |
| Q90621792 | Risk of neurological disorders in patients with European Lyme neuroborreliosis. A nationwide population-based cohort study |
| Q64088206 | Rivaroxaban: A Possible Cause of Guillain-Barre Syndrome |
| Q93095306 | Role of IV Immunoglobulin in Indian Children With Guillain-Barré Syndrome |
| Q95650344 | SARS-CoV-2 Infection Leads to Neurological Dysfunction |
| Q89881723 | Seasonal influenza vaccine and Guillain-Barré syndrome: A self-controlled case series study |
| Q59602093 | Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial |
| Q63246818 | Serum Folate Correlates with Severity of Guillain-Barré Syndrome and Predicts Disease Progression |
| Q101387290 | Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients |
| Q66679108 | Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report |
| Q90173739 | Siglecs at the Host-Pathogen Interface |
| Q96813771 | Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems |
| Q47885510 | Single-session communication with a locked-in patient by functional near-infrared spectroscopy. |
| Q56604848 | Sleep and psychiatric abnormalities in Gullian Barré Syndrome |
| Q41991434 | Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study |
| Q57928128 | Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study |
| Q51172720 | Successfully Managed Acute Transverse Myelitis Related to Scrub Typhus and Serial Image Findings. |
| Q90356164 | Superimposed Guillain-Barré Syndrome (GBS) in pediatric hypoxic brain injury |
| Q94452895 | Surgery and Guillain-Barré Syndrome: A Single-Center Retrospective Study Focused on Clinical and Electrophysiological Subtypes |
| Q91132464 | Surgery and risk of Guillain-Barré syndrome: A French nationwide epidemiologic study |
| Q90082688 | Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries |
| Q92252833 | Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season |
| Q90295743 | Symmetric polyneuropathy after viral symptomatology - not always Guillain-Barré Syndrome |
| Q57796434 | Synthesis of Core Oligosaccharides of Lipooligosaccharides from Campylobacter jejuni, a Putative Cause of Guillain-Barré Syndrome |
| Q59245655 | Systematic review of factors associated with the development of guillain-barré syndrome 2007 to 2017: what has changed? |
| Q90025033 | The Association of Guillain-Barré Syndrome with Pulmonary Tuberculosis: Chance or Causal? |
| Q56000910 | The Axon-Myelin Unit in Development and Degenerative Disease |
| Q52571849 | The Immunotherapy of Guillain-Barré Syndrome. |
| Q26261645 | The International Classification of Functioning Framework in Zika-Related Disabilities |
| Q92073451 | The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons |
| Q47430940 | The Role of Immunoglobulin in the Treatment of Immune-Mediated Peripheral Neuropathies |
| Q99255088 | The associations between nutritional and functional status during recovery from Guillain-Barré syndrome: a retrospective study |
| Q95578358 | The authors reply |
| Q88446025 | The complement story in Guillain-Barré syndrome: from pathogenesis to therapy |
| Q92495604 | The effectiveness and safety of acupuncture therapy for Guillain-Barré syndrome: A systematic review and meta-analysis protocol |
| Q97426603 | The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings |
| Q26247068 | The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact |
| Q90700518 | The immunobiology of autoimmune encephalitides |
| Q29364922 | The influence of health concern on travel plans with focus on the Zika virus in 2016 |
| Q54232538 | The neurological complications of chikungunya virus: A systematic review. |
| Q101237884 | The neurological sequelae of pandemics and epidemics |
| Q39558493 | The pathogenic relevance of αM-integrin in Guillain-Barré syndrome. |
| Q98729169 | The prognostic value of demyelinating electrophysiologic findings and cerebrospinal fluid protein levels in acute inflammatory demyelinating polyneuropathy |
| Q101141112 | The role of brain innate immune response in lysosomal storage disorders: fundamental process or evolutionary side-effect? |
| Q92350199 | The role of infections in autoimmune encephalitides |
| Q39295050 | The role of regulatory T cells in nervous system pathologies |
| Q47099059 | The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study. |
| Q91077284 | Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy |
| Q92240412 | Thyrotoxic Periodic Paralysis: A Spine Consultation |
| Q64070293 | Toll-like receptor-4 299Gly allele is associated with Guillain-Barré syndrome in Bangladesh |
| Q92866103 | Toscana virus associated with Guillain-Barré syndrome: a case-control study |
| Q38633484 | Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice. |
| Q102972544 | Trauma-Related Guillain-Barré Syndrome: Systematic Review of an Emerging Concept |
| Q39005958 | Treatment dilemmas in Guillain-Barré syndrome |
| Q100530835 | Triggers of posterior reversible encephalopathy in Guillain-Barre syndrome |
| Q90465116 | Tuberculous meningitis: An unlikely cause of Guillain-Barre syndrome |
| Q39000208 | Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe? |
| Q91599914 | Ultrastructural characterization of mitochondrial damage in experimental autoimmune neuritis |
| Q99608500 | Unique repertoire of anti-carbohydrate antibodies in individual human serum |
| Q50528668 | Unusual sensory variant of Guillain-Barré syndrome. |
| Q91723105 | Update on Campylobacter vaccine development |
| Q90369658 | Update: the Miller Fisher variants of Guillain-Barré syndrome |
| Q92903876 | West Nile Virus infection triggering autoimmune encephalitis: Pathophysiological and therapeutic implications |
| Q28353939 | Zika Virus Infection and Guillain-Barré Syndrome in Three Patients from Suriname |
| Q28114477 | Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain–Barré Syndrome: Systematic Review |
| Q112076755 | Zika Virus Non-Structural Protein 1 Antigen-Capture Immunoassay |
| Q38156583 | Zika Virus Outbreak - Should assisted reproduction patients avoid pregnancy? |
| Q58084172 | Zika Virus and Neurologic Disease |
| Q38158918 | Zika Virus as an Emerging Neuropathogen: Mechanisms of Neurovirulence and Neuro-Immune Interactions |
| Q52586122 | Zika Virus in the Male Reproductive Tract. |
| Q90666106 | Zika Virus infection and Guillain-Barré syndrome in Northeastern Mexico: A case-control study |
| Q104491626 | Zika and dengue but not chikungunya are associated with Guillain-Barré syndrome in Mexico: A case-control study |
| Q43038393 | Zika virus and Guillain-Barré syndrome |
| Q55084470 | Zika virus and Guillain-Barré syndrome in Bangladesh. |
| Q27010576 | Zika virus as a causative agent for primary microencephaly: the evidence so far |
| Q41921601 | Zika virus disease-associated Guillain-Barré syndrome-Barranquilla, Colombia 2015-2016. |
| Q90066628 | Zika virus encephalitis in immunocompetent mice is dominated by innate immune cells and does not require T or B cells |
| Q45324658 | Zika virus in French Polynesia 2013-14: anatomy of a completed outbreak |
| Q30243868 | Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypes |
| Q56762711 | Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barre syndrome: systematic review |
| Q40050581 | Zika virus infection in Brazil and human rights obligations |
| Q54241812 | Zika virus infection in the returning traveller: what every neurologist should know. |
| Q92489838 | Zika virus infection: an update |
| Q24244835 | Zika virus: An update on epidemiology, pathology, molecular biology, and animal model |
| Q24289640 | Zika virus: oral healthcare implications |
| Q52590193 | [Approach for identifying of treatment option for pediatric patients in Guillain-Barre syndrome considering results of pharmacoeconomic analysis]. |
| Q99550263 | [Association of motor nerve conduction block with different subtypes of childhood Guillain-Barré syndrome] |
| Q53737471 | [Paraplegia after hematopoietic stem cell transplantation]. |
Search more.